Fluoxakalner is a Kv7.2 and Kv7.3 potassium channel opener which is under investigation for potential medical use. Its EC50Tooltip half-maximal effective concentration for opening Kv7.2 and Kv7.3 channels has been found to be 360 nM. The drug produces analgesic effects in rodents and without causing sedation or locomotor changes. In addition, it did not inhibit various cardiac ion channels. The chemical synthesis of fluoxakalner has been described. Fluoxakalner was first described in the scientific literature by Wei Xiang and colleagues in 2026. It was developed as a replacement for retigabine, which was withdrawn from the market due to toxicity. Fluoxakalner avoids oxidative metabolites like retigabine's thought to be responsible for said toxicity.
See also Retigabine Flupirtine Pynegabine Azetukalner Opakalim
References